Evaluations of motelukast as add on therapy (corticosteroid sparing effect) to inhaled cortocosteroids in patients with chronicpersistent Asthma

International Journal of Drug Development and Research

Volumn 3, Issue 1, 2011, Pages 01-05

  Narmadha, M P ^a   John, Jimy ^a   Nagarajan, M ^a   Murugesh, N ^b  

^a SWAMY VIVEKANANDHA COLLEGE OF PHARMACY   (India)

^b MADURAI MEDICAL COLLEGE   (India)

Author keywords

Asthma; Inhaled corticosteroids; Montelucast

Indexed keywords

BUDESONIDE; FORMOTEROL; MONTELUKAST;

ADD ON THERAPY; ADOLESCENT; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHODILATATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; SCORING SYSTEM; SEVERE PERSISTENT ASTHMA;

EID: 79955926392     PISSN: None     EISSN: 09759344     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Malcon R. Sear, Evidence Based Asthma Management, "Natural History and Epidemiology", B.C. Decker Inc., London, 2001, pp. 1-12.
2. National Heart, Lung and Blood Institute (NHLBI),1985.
3. Richard A. Nicklas and Albert I. Sheffer, Asthma Management for New Millennium, "Guidelines for Asthma - Relating Local Needs and Global Initiatives Adis International ltd., pp. 37-44.
4. Product Manual on Montelukast by Ranbaxy Labs, 2001
5. OJ. Dempers, Leukotriene Receptor Antagonist Therapy, Postgrad. Med J, December 2000; 76:767-773.
6. Lipworth, B.J., Leukotriene Receptor Antagonist, Lancet 1999; 353:57-62 (Medline).
7. Montelukast - Adis Drug evaluation, April 2000, 59: 891-928.
8. Kannesis, F., Richter, K., Janicki, S., Schlesis, M.B., Jorres, RA and Magnussen, H., Dose Reduction of Inhaled Corticosteroids under concomitant medication with montelukast inpatients with Asthma, European Respiratory journal, November 2002, Vol. 20 No.5, pp. 1090 -1097(8).
9. Tohda, K., Fujimura, M., Taniguchi, H., Takagi, K., Igrashi, T., Yashuhara, H., Takalashi, K., and Nakajima, S., Leukotriene Receptor Antagonist, Montelukast can reduce the need for inhaled steroids while maintaining the clinical Stability of Asthmatic patients, clinical and Experimental Allergy, August 2002, Vol. 32, No.8 pp.1180-1186(7).
10. David B., Price, M. B., Michael, Y., Rouleau, M.D. and Christopher, B., Use of Montelukast in Tapering Inhaled Corticosteroid Therapy: An open Label, 48 Week trial, Current Therapeutic Research, November 2001, Vol.62, Issue 11, pp. 743 - 755.
11. Shah, A.R., Which is more Steroid Sparing in Persistent bronchial Asthma?, Journal of Allergy and Clinical Immunology, February 2004, Vol. 113, Issue 2,Supplement 1,pp. S34-S35.
12. Claes-goran lofdahl, Theodore F.Reiss, Jonathan ALeff, Elliot Israel and Michel J.Noonan, Randomized Placebo Controlled Trial of Effect of a Leukotriene Receptor Antagonist, montelukast on Tapering Inhaled Corticosteroids in Asthmatic patients, BMJ, July 1999,319:87-90.
13. The British guidelines on asthma management 1995, Review and Position Statement, Thorax 1997;52(90001):S1-S2(February).
14. Riccioni, G., Ilio, C.D. and D Orazio, An Update of the Leukotriene modulaters for the Treatment of Asthma, Expert Opinion on Investigational Drugs, July 2004, Vol.13,No.7,pp.763-776(14).
15. Price, D.B., Hernandez, D., Magyar, P., Fiterman, J., Bech, K.M., James, I.G., Konstantopoulos, S., Rojas, R., Van Noored, J.A., Pons, M., Gilles, I.andLeff, J.A., Randomized Controlled Trial of Montelukast plus Inhaled Budesonide Versus Double Dose Inhaled Budesonide in Adult Patient with Asthma(COMPACT STUDY),Thorax 2003,58:211-216.
16. Yildirim, Z., Ozlu, T., Bulbul, Y. and Bayram, H., Addition of Montelukast Versus Double Dose of Inhaled Budesonide in moderate Persistent Asthma, Respirology, June 2004,Vol.9,No.2,pp.243-248(6).
17. th Edition, the Definition of asthma: Its Relationship to other Chronic obstructive lung Diseases", Arnold Publishers, 2002, p. 1-32.
18. th Edition, p.712.
19. Richard Hubbard and Anne Tattersfield, Inhaled Corticosteroids, Bone Mineral Density and fracture in older people, drugs and ageing, 2004,Vol.21,No.10,pp.631-638(8).